Inhibiting cholesteryl ester transfer protein (CETP) activity raises high-density lipoprotein cholesterol levels and may be cardioprotective. However, an initial clinical trial with a CETP inhibitor was stopped prematurely because of increased cardiovascular disease (CVD) events in treated patients. Data relating circulating CETP mass to CVD incidence in the community are also conflicting. Therefore, we related routinely assayed plasma CETP activity to the incidence of CVD events on follow-up (average, 15 years) in the offspring cohort of the Framingham Heart Study. In multivariable analyses adjusted for standard CVD risk factors, plasma CETP activity was related inversely to the incidence of CVD events, a finding that remained robust in time-dependent models updating CVD risk factors every 4 years on follow-up and was maintained in analyses of incident "hard" CVD events. These observational data based on prospective follow-up of a large community-based sample require confirmation. If confirmed, our findings would call into question the use of CETP inhibition as a strategy for lowering CVD risk. See p 2414.
Glycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients
Patients on maintenance dialysis treatment experience an excess mortality, which is highest among diabetic patients. Cardiac disease represents the leading cause of death, particularly sudden cardiac death. Evidence suggests that poor glycemic control may affect the arrhythmogenesis of patients with kidney failure because it affects the development of comorbidities, electrolyte balance, function of potassium and calcium channels, and sympathetic activity. In the present study of 1255 hemodialysis patients with type 2 diabetes mellitus, poor glycemic control as represented by elevated levels of glycohemoglobin A 1c (HbA 1c ) was associated with an increased risk of sudden cardiac death. Patients with an HbA 1c Ͼ8% had a 2-fold higher risk of sudden death compared with those with an HbA 1c Յ6% independently of other known risk factors. Although myocardial infarction was not affected, the risks of the combined primary end point and mortality significantly increased at higher levels of HbA 1c and were explained mainly by the impact of glycemic control on sudden cardiac death. By pointing out the importance of distinguishing the pathophysiologically different causes of death, the present study offers new perspectives for future research on glucose control in populations with a high incidence of sudden death. Importantly, these results may suggest novel therapeutic strategies in diabetic hemodialysis patients, in whom sudden cardiac death accounts for a quarter of all deaths. Whether tight glucose control decreases the risk of sudden death without causing side effects remains to be studied. See p 2421.
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction
Hyperglycemia is a strong predictor of mortality in patients hospitalized with acute myocardial infarction. Professional society guidelines have accordingly advised glucose control in hyperglycemic patients. These same guidelines also recommend avoiding hypoglycemia, even though the association between hypoglycemia and adverse outcomes in acute myocardial infarction patients is controversial. We conducted a post hoc analysis of data from 2 large trials of glucose-insulin-potassium infusion in acute myocardial infarction and compared the prognostic significance of hypoglycemia and hyperglycemia with normoglycemia in 30 536 patients. Both hypoglycemia (glucose Յ60 mg/dL) and hyperglycemia (glucose Ն140 mg/dL) at admission predicted higher 30-day mortality. However, this U-shaped relationship became attenuated in the 24-hour postadmission period, during which hyperglycemia still predicted death but hypoglycemia no longer was prognostic. Results were similar in patients with a history of diabetes. Furthermore, even though hypoglycemia was more common in patients receiving insulin (glucose-insulin-potassium) therapy than in patients who did not, hypoglycemia did not predict death in either insulin-treated or untreated patients. This study suggests that hypoglycemia may not be a direct mediator of adverse outcomes in acute myocardial infarction patients and provides some reassurance to clinicians who are concerned about overlooking or unintentionally inducing hypoglycemia in these patients. See p 2429.
Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall
Telomere erosion is a central component of aging, and telomereassociated proteins regulate cellular senescence and survival. To elucidate the cellular mechanisms of the vasculoprotective effects of physical exercise, mice were randomized to voluntary running or no running wheel conditions. Exercise upregulated telomerase activity and telomere regulating proteins in the thoracic aorta and in circulating mononuclear cells compared with sedentary controls and reduced the expression of vascular apoptosis regulators such as cell-cycle-checkpoint kinase 2, p16, and p53. Mice preconditioned by voluntary running exhibited a marked reduction in lipopolysaccharide-induced endothelial apoptosis. Transgenic mouse studies showed that endothelial nitric oxide synthase and telomerase reverse transcriptase synergize to confer endothelial stress resistance after physical activity. To test the significance of these data in humans, telomere biology in circulating leukocytes of young and middle-aged track and field athletes was analyzed. Peripheral blood leukocytes isolated from endurance athletes showed increased telomerase activity, expression of telomere-stabilizing proteins, and downregulation of cell-cycle inhibitors compared with untrained individuals. Older athletes were characterized by reduced leukocyte telomere erosion compared with untrained controls. We therefore conclude that physical activity represents an "antiaging" intervention mediating cellular antisenescent and antiapoptotic vascular effects. See p 2438.
Integrative Predictive Model of Coronary Artery Calcification in Atherosclerosis
Presymptomatic prediction of late-onset diseases is one of the greatest promises of genetic medicine and is at the heart of personalized medicine. This study describes a model of preclinical atherosclerosis based on genetic and clinical data. This model predicts the presence of coronary artery calcification with 85% accuracy. We assessed 712 healthy Americans of European descent 45 to 84 years of age for the presence of coronary artery calcification and studied their genotypes for 2882 single-nucleotide polymor- 15, 2009 phisms, subtle variations in individuals' genomes. We used a methodology known as Bayesian networks, born at the confluence of statistics and artificial intelligence, to integrate these genetic data and relevant clinical information into a coherent network model that predicted the presence of coronary calcification. The model contained 13 single-nucleotide polymorphisms and 5 clinical variables (sex, age, weight, smoking, and diabetes mellitus). This model outperformed both the model built from purely genetic data and the model built with clinical information alone. In this way, the present study demonstrates the improved predictive performance of joint consideration of genetic and clinical contributions to a subclinical measure of atherosclerosis. Because the predictive ability of our model is an improvement over the previous best-performing associative tests, this approach has the potential to improve individual risk prediction of arteriosclerosis through the development of genetic tests. Furthermore, the model described in the present study may lead to improved clinical and mechanistic models of atherosclerosis progression and to the identification of novel molecular targets for drug development. See p 2448.
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Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention: A National Registry of Myocardial Infarction Analysis
This report uses the National Registry of Myocardial Infarction to better understand patterns of reperfusion therapy use in hospitals with percutaneous coronary intervention capability. The superiority of primary percutaneous coronary intervention versus fibrinolytic therapy in the setting of ST-segment elevation myocardial infarction has been well established, yet its use is not universal at hospitals with this capability in the United States, with more than one third of these facilities also reporting the use of fibrinolytic therapy during recent years. We found that although primary percutaneous coronary intervention use has been increasing steadily over recent years, a substantial number of patients with ST-segment elevation myocardial infarction continue to receive fibrinolytic therapy. This finding is particularly concerning in that primary percutaneous coronary intervention may not be used universally even in high-risk groups of patients who may stand to gain the most from it. We believe these findings have broad implications for the design of future ST-segment elevation myocardial infarction systems of care. See p 2455.
Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis
Inflammation and matrix degradation are the hallmarks of high-risk atherosclerosis that leads to myocardial infarction and stroke. Many previous studies have identified various pathways leading to atherosclerotic lesions in mice; however, this knowledge has thus far failed to translate to effective therapeutic strategies. Toll-like receptors (TLRs), key players in innate immunity, are upregulated in atherosclerotic lesions, but their functional role in human atherosclerosis is unknown. We previously showed that cytokine, chemokine, and matrix metalloproteinase production, in an in vitro model of human atherosclerosis, is dependent on nuclear factor-B, a key transcription factor downstream of TLR signaling. Here we have explored the effects of blocking TLR-2, TLR-4, and myeloid differentiation primary response gene 88, a signaling adaptor shared by most TLRs and interleukin-1 receptor. Blockade of TLR-2 markedly reduced the production of proinflammatory mediators and matrix metalloproteinases. Similar effects were observed with myeloid differentiation primary response gene 88 inhibition, indicating that production of proinflammatory cytokines, chemokines, and matrix metalloproteinases in human atherosclerotic lesions is myeloid differentiation primary response gene 88 dependent. Our data show for the first time that in human atherosclerosis, TLR-2 signaling through myeloid differentiation primary response gene 88 is a rate-limiting step for both inflammation and matrix degradation. This study, by identifying a specific inflammatory pathway that may mediate the instability of cardiovascular lesions, forms the basis for the development of therapeutic agents targeting TLR-2 in cardiovascular disease. See p 2462.
Reduction of Circulating Soluble Fms-Like Tyrosine Kinase-1 Plays a Significant Role in Renal Dysfunction-Associated Aggravation of Atherosclerosis
Chronic kidney disease is a worldwide public health problem not only because it leads to end-stage renal failure but also because it is an independent risk factor for atherosclerosis-related cardiovascular events. Accumulating evidence indicates atherosclerosis is usually worsened in patients with renal dysfunction, and the risk of cardiovascular disease increases sharply as the estimated glomerular filtration rate declines. Additionally, more than 50% of deaths among patients with end-stage renal failure are due to cardiovascular events. Although it is clear that most cardiovascular events in renal dysfunction result from atherosclerosis, the underlying molecular mechanism responsible for the worsening of atherosclerosis in renal dysfunction is not yet fully understood. Consequently, an effective therapeutic strategy is still lacking. Here, we examine the role played by soluble fms-like tyrosine kinase-1 (sFlt-1), an endogenous antagonist of the proatherogenic cytokine placental growth factor (PlGF), in the worsening of atherosclerosis seen in patients with renal dysfunction and in an animal model of renal failure. This report describes our novel observation that circulating sFlt-1 levels are reduced in patients with renal dysfunction in proportion to the severity of the disease, whereas there is no change in plasma PlGF levels. Moreover, renal production of sFlt-1 is also diminished in patients with renal dysfunction, and replacement treatment with recombinant human sFlt-1 reduces five-sixths-nephrectomy-induced worsening of atherosclerosis of apolipoprotein E-deficient mice. Thus, the present findings provide a new insight into the molecular mechanism for worsening of atherosclerosis in renal dysfunction and could lead to a new effective therapeutic strategy. See p 2470.
Impaired Fibrillin-1 Function Promotes Features of Plaque Instability in Apolipoprotein E-Deficient Mice
Atherosclerosis mainly affects the intima, but important changes also occur in the media, including fragmentation of the elastic fibers and medial atrophy. An important consequence of these medial changes is an increase in arterial stiffness. Previous studies have shown that arterial stiffness is an independent predictor of cardiovascular mortality. However, it is unknown whether arterial stiffness is only the consequence of atherosclerosis or whether arterial stiffness contributes directly to the progression of atherosclerosis. Therefore, this study investigated the interaction between arterial stiffness and atherosclerosis. Our results show that this interaction is bidirectional. Arterial stiffness enhances the progression of atherosclerosis, which in turn accelerates arterial stiffening. This interaction leads to a vicious circle, resulting in the development of larger and more unstable atherosclerotic plaques. One of the mechanisms linking arterial stiffness to the progression of atherosclerosis is pulse pressure. Arterial stiffening is associated with an elevated pulse pressure, which promotes plaque instability through multiple effects, including induction of apoptosis of smooth muscle cells. Our results indicate that inhibition or deceleration of arterial stiffening may have a beneficial effect on cardiovascular mortality and morbidity. See p 2478.
